RESUMEN
CMF regimen contains Cyclophosphamide. Methotrexate and 5-fluorouracil which was developed in "Istituto Nazionale Tumori in Milan and has found to be effective in both pie-menopausal and post-menopausal breast cancer patients. Since it contains some hepatotoxic drug components so we tried to evaluate the cumulative hepatotoxicity of this combination, both in acute and chronic phases. In case of acute toxicity the regimen is found to be safe. However in case of chronic toxicity, it is found to produce mild effects in patients receiving less than three cycles and moderate effects in patients receiving more than three cycles. This represents that benefit versus risk should be assessed before giving CMF regimen to the patients, especially when other drugs like analgesics or antidepressants are prescribed with it
RESUMEN
The hepatotoxic potential of combination protocol CMF [Cyclophosphamide Methotrexate and 5-fluorouracil] is well documented in breast cancer patients, receiving CMF as an adjuvant after surgery. Icterence, a herbal medicine, is believed to be effective in cases of hepatic disorders. This study is aimed to evaluate the hepatic status of patients maintained on the combination of CMF and Icterene. This was compared with controls and those patients who were receiving CMF protocol only. Statistically insignificant alternations in different hepatic enzymes were observed, thus not imparting any benefit to CMF induced hepatotoicity